Cargando…

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus

Vesicular stomatitis virus (VSV) is a promising oncolytic virus (OV) against different malignancies, including pancreatic ductal adenocarcinoma (PDAC). Our previous studies have demonstrated that VSV-based OVs are effective against the majority of tested human PDAC cell lines. However, some PDAC cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goad, Dakota W., Bressy, Christian, Holbrook, Molly C., Grdzelishvili, Valery Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703189/ https://www.ncbi.nlm.nih.gov/pubmed/34977342 http://dx.doi.org/10.1016/j.omto.2021.11.019

Ejemplares similares

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions
por: Holbrook, Molly C., et al.
Publicado: (2021)

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
por: Goad, Dakota W., et al.
Publicado: (2023)

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Hastie, Eric, et al.
Publicado: (2016)

Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells
por: Seegers, Sara L., et al.
Publicado: (2020)

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
por: Bressy, Christian, et al.
Publicado: (2017)

Cellular Proteins Associated with the Interior and Exterior of Vesicular Stomatitis Virus Virions
por: Moerdyk-Schauwecker, Megan, et al.
Publicado: (2014)

Cell Type Mediated Resistance of Vesicular Stomatitis Virus and Sendai Virus to Ribavirin
por: Shah, Nirav R., et al.
Publicado: (2010)

Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach
por: Moerdyk-Schauwecker, Megan, et al.
Publicado: (2009)

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
por: Simovic, Boris, et al.
Publicado: (2015)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells
por: Garijo, Raquel, et al.
Publicado: (2014)

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
por: Heiber, Joshua F., et al.
Publicado: (2011)

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
por: Bourgeois-Daigneault, Marie-Claude, et al.
Publicado: (2016)

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells
por: Kim, Teddy E., et al.
Publicado: (2021)

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells
por: Corredor, Juan C, et al.
Publicado: (2016)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation
por: Wawra, Simon, et al.
Publicado: (2023)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models
por: Le Boeuf, Fabrice, et al.
Publicado: (2017)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein
por: Stegelmeier, Ashley A., et al.
Publicado: (2020)

Aphthæ, or Vesicular Stomatitis of the Horse
por: Hutcheon, D.
Publicado: (1898)

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines
por: Bridle, Byram W, et al.
Publicado: (2013)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

RIG‐I‐mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus
por: Zhang, Pengfei, et al.
Publicado: (2022)

The synthetic futures of vesicular stomatitis virus
por: Overend, Christopher, et al.
Publicado: (2012)

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia
por: Betancourt, Dillon, et al.
Publicado: (2015)

Autophagy Gene Activity May Act As a Key Factor for Sensitivity of Tumor Cells to Oncolytic Vesicular Stomatitis Virus
por: Nabizadeh, Arezoo, et al.
Publicado: (2016)

Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis
por: AuYeung, Amanda W. K., et al.
Publicado: (2021)

Cell Cycle Arrest in G(2)/M Phase Enhances Replication of Interferon-Sensitive Cytoplasmic RNA Viruses via Inhibition of Antiviral Gene Expression
por: Bressy, Christian, et al.
Publicado: (2019)

Atomic model of vesicular stomatitis virus and mechanism of assembly
por: Zhou, Kang, et al.
Publicado: (2022)

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective
por: Kleinlützum, Dina, et al.
Publicado: (2017)

MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells
por: Bayne, Robert S., et al.
Publicado: (2020)

Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma
por: Makielski, Kelly M., et al.
Publicado: (2023)

EFFECT OF FORMALIN ON THE VIRUS OF VESICULAR STOMATITIS OF HORSES
por: Olitsky, Peter K., et al.
Publicado: (1928)

Cannot write session to /tmp/vufind_sessions/sess_5fj7jf65ll05jinngdg6tkf1i1